Drug news
Alogliptin (Takeda) filed at EMA for Type 2 Diabetes
The European Medicines Agency has accepted for review alogliptin,a selective dipeptidyl peptidase IV (DPP-4) inhibitor from Takeda for Type 2 Diabetes. The filing is based on trials involving more than 11,000 patients and several ongoing studies, including the EXAMINE trial which is evaluating cardiovascular endpoints following treatment with alogliptin. The FDA has isssued a Complete Response Letter in respect to the American application.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins